Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem Technologies (FRA:0JQ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioStem Technologies Net Margin % Related Terms
BioStem Technologies Net Margin % Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (FRA:0JQ) has a Net Margin % of -113.58% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #415 out of 945 companies in the Biotechnology industry, placing it in the top 43.9%.
Is BioStem Technologies' Net Margin % too high?
BioStem Technologies' current Net Margin % is -113.58%. Based on the distribution chart, BioStem Technologies ranks #415 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Net Margin % compare to ?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #415 out of 945 companies for Net Margin %. This puts BioStem Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Net Margin % is -113.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (FRA:0JQ) has a current Net Margin % of -113.58%. The current Net Margin % is -113.58%. BioStem Technologies' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioStem Technologies (FRA:0JQ), the current Net Margin % is -113.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
35GF Score
Get the complete analysis for FRA:0JQ
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0JQ has been successfully added to your 
